ARWR Form 144: Insider Proposed Sale of 611 Shares Worth $12,190

Form 144 filed for ARWR reports a proposed sale of 611 common shares through Merrill Lynch on the NASDAQ with an aggregate market value of $12,190.05 and 138,257,550 shares outstanding.

Rhea-AI Filing Summary

Form 144 filed for ARWR reports a proposed sale of 611 common shares through Merrill Lynch on the NASDAQ with an aggregate market value of $12,190.05 and 138,257,550 shares outstanding. The notice specifies an approximate sale date of 08/13/2025.

The filing lists the acquisition history for the shares being sold: grants received as compensation on 01/04/2022 (3,485), 01/02/2023 (15,802), 01/04/2023 (12,557), 01/04/2024 (1,167), 01/08/2024 (4,950) and 01/04/2025 (27,271), with the named transferor in those records shown as James Hamilton. The form indicates no securities sold in the past three months and includes the required representation that the seller does not possess undisclosed material information.

Insights

Securities Analyst

TL;DR: Small proposed sale disclosed; details show shares were received as compensation over multiple years.

The filing documents a proposed sale of 611 common shares via Merrill Lynch on NASDAQ with an aggregate market value of $12,190.05 and outstanding shares of 138,257,550. The seller's acquisition history is fully listed and characterized as compensation from James Hamilton on specific dates from 2022–2025. The notice also records that no other securities were sold in the prior three months and includes the standard representation regarding material nonpublic information. For investors, this is a routine insider sale disclosure rather than a corporate operational update.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure showing insider-originated compensation shares and a planned brokered sale.

The Form 144 supplies the regulatory detail necessary for a proposed sale: broker name (Merrill Lynch), exchange (NASDAQ), number of shares (611), aggregate market value ($12,190.05) and the acquisition trail for those shares labeled as compensation with James Hamilton identified as the source across multiple dates. The filing also asserts the signer is unaware of undisclosed material adverse information. This presentation aligns with routine governance and disclosure expectations for executive or insider sales.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ARWR Form 144 disclose?

The notice discloses a proposed sale of 611 common shares via Merrill Lynch on NASDAQ with an aggregate market value of $12,190.05 and 138,257,550 shares outstanding.

When is the approximate sale date listed on the ARWR Form 144?

The filing lists the approximate date of sale as 08/13/2025.

How were the shares being sold acquired according to the filing?

The shares were acquired as compensation on multiple dates: 01/04/2022 (3,485), 01/02/2023 (15,802), 01/04/2023 (12,557), 01/04/2024 (1,167), 01/08/2024 (4,950), and 01/04/2025 (27,271).

Who is named in the filing as the source of the acquired shares?

The acquisition table names James Hamilton as the person from whom the compensation shares were listed as acquired.

Does the filing report any securities sold by the person in the past three months?

No. The filing's section on sales during the past three months states Nothing to Report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2025 - 05:57 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001830755
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARROWHEAD PHARMACEUTICALS, INC.
SEC File Number	001-38042
Address of Issuer	177 E COLORADO BLVD SUITE 700 PASADENA CALIFORNIA 91105
Phone	626-696-4702
Name of Person for Whose Account the Securities are To Be Sold	Hamilton James C
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 75 Rockefeller Plz Flr 2 New York NY 10019	611	12190.05	138257550	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/04/2022	Compensation	James Hamilton			3485	08/13/2025	Compensation
Common	01/02/2023	Compensation	James Hamilton			15802	08/13/2025	Compensation
Common	01/04/2023	Compensation	James Hamilton			12557	08/13/2025	Compensation
Common	01/04/2024	Compensation	James Hamilton			1167	08/13/2025	Compensation
Common	01/08/2024	Compensation	James Hamilton			4950	08/13/2025	Compensation
Common	01/04/2025	Compensation	James Hamilton			27271	08/13/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/13/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/24/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James Hamilton
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)